Efficacy results of Otsuka’s delamanid (Deltyba™) for XDR-TB published in the New England Journal of Medicine

Analysis of data from Phase IIb trial showed that delamanid plus a background regimen may be a promising treatment option in complex, difficult-to-treat XDR-TB patients.ⁱ